EUCTR2007-000329-22-GB进行中（未招募）1 期
A randomised, double blind, crossover pilot study of intravenous buprenorphine versus intravenous buprenorphine/ naloxone in patients with chronic pain.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •i) Written informed consent.
- •ii) Male or female patients aged 18 years or over.
- •iii) Patients with a recognised chronic pain condition greater than 3 months duration that has been diagnosed by a pain management specialist.
- •iv) Patients with moderate to severe chronic pain (defined as a minimum of 40 mm pain score on the 100mm pain visual analogue scale at screening and a minimum average daily pain score of 4 on an 11-point Likert scale (0, no pain; 10, worst pain ever experienced) during pre-treatment.
- •v) Adequate renal function (serum creatinine females <130 micro mol/l: males <150 micro mol/l).
- •vi) Liver enzymes (AST or ALT) less than twice the upper limit of normal. Alkaline phosphatase less than twice the upper limit of normal.
- •vii) Bilirubin within the normal range.
- •viii) Patients stabilised on regular doses of step II analgesics for at least 2 weeks prior to the pre-treatment period of the study. Regular doses of analgesia must be continued during the study period (except for the two treatment days).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •i) Woman of childbearing potential, who are pregnant or lactating, seeking pregnancy or failing to take adequate contraceptive precautions, i.e. an oral contraceptive, an approved hormonal implant, an intrauterine device or condoms/diaphragm and spermicide). A woman of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone a hysterectomy or surgical sterilisation, e.g. bilateral tubal ligation, bilateral ovariectomy (oophorectomy).
- •ii) Patients receiving sustained-release formulations of opioid analgesics or tramadol.
- •iii) Patients who have a history of experiencing intolerable opioid analgesic side effects.
- •iv) Patients who are receiving tricyclic antidepressants, anticonvulsants, membrane stabilisers or steroids for the pain if the doses have not been stable for the 2 weeks prior to the pre-treatment period of the study or if doses are likely to change during the study.
- •v) Patients who are receiving monoamine oxidase inhibitors, phenobarbital, carbamazepine, phenytoin, rifampicin, gestodene, troleandomycin, ketoconazole, norfluoxetine, ritonavir, indinavir or saquinavir.
- •vi) Abnormal serum electrolytes, which in the investigators opinion would exclude the patient from this study.
- •vii) Haemoglobin outside the normal limits and white blood cell count below the lower limit of normal or above 12 x 10^9/l.
- •viii) Patients who have anxiety or depression to such a degree that the investigators judge that participation in the study would be detrimental to their mental health.
- •ix) Patients who are unable to understand and complete assessment questionnaires in English and those unable to complete VAS scales.
- •x) Concurrent surgery, radiotherapy, chemotherapy or nerve blocks and those who have received this treatment 4 weeks prior to the study.
- •xi) Patients who are receiving, or have received buprenorphine based analgesia in the last 14 days.
- •xii) Patients who have been in another clinical study within the last 3 months.
- •xiii) Patients with a previous history of allergy or intolerance to buprenorphine, naloxone or paracetamol.
- •xiiii) Patients who have been previously randomised into the study.
研究者
相似试验
尚未招募
3 期
Do bisphosphonate tablets improve bone health in patients on dialysisEnd Stage Kidney Diseasefracture riskRenal and Urogenital - Kidney diseaseMusculoskeletal - OsteoporosisACTRN12620000321943Westmead Hospital Research and Education Network114
已完成
不适用
A double-blind, randomized controlled pilot study of olive leaf extracts(OLE) for the prevention of periodontal diseases.Periodontal diseasesJPRN-UMIN000005309Department of Preventive Dentistry, Osaka University Graduate School of Dentistry45
进行中（未招募）
不适用
A trial comparing the safety and efficacy of insulin degludec and insulin glargine, both with insulin aspart as mealtime insulin in subjects with type 1 diabetesMedDRA version: 17.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 1EUCTR2012-001930-32-PLovo Nordisk A/S446
进行中（未招募）
不适用
A randomised, double blind, 2-way crossover trial of 8 days repeat dosing with intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)Seasonal allergic rhinitisMedDRA version: 9.1Level: LLTClassification code 10039776Term: Seasonal allergic rhinitisEUCTR2007-005302-44-ATGlaxoSmithKline Research & Development Limited70
已完成
不适用
SYMBIOTiC Study – SYMptom, microBIOme and dieT in Chronic Kidney DiseaseSymptom burdenQuality of lifeUraemic syndromeRenal and Urogenital - Kidney diseaseDiet and Nutrition - Other diet and nutrition disordersChronic Kidney DiseaseACTRN12619000442101niversity of Wollongong28